Myriad Genetics (MYGN) Receivables (2010 - 2026)

Myriad Genetics (MYGN) has reported Receivables for 17 consecutive years, with $123.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Receivables rose 2.82% year-over-year to $123.8 million; the TTM figure through Mar 2026 stood at $123.8 million (up 2.82% YoY), while the FY2025 annual figure was $115.3 million, down 4.87% from the prior year.
• Receivables advanced to $123.8 million in Q1 2026 per MYGN's latest filing, from $115.3 million in the prior quarter.
• Across five years, Receivables topped out at $137.0 million in Q2 2025 and bottomed at $101.6 million in Q4 2022.
• Historically, Receivables has averaged $116.1 million across 5 years, with a median of $117.8 million in 2024.
• Annual changes were most pronounced in 2023 — Receivables gained 17.11% — and 2025, when it slipped 6.13%.
• Myriad Genetics' Receivables stood at $101.6 million in 2022, then increased by 12.5% to $114.3 million in 2023, then advanced by 6.04% to $121.2 million in 2024, then slipped by 4.87% to $115.3 million in 2025, then grew by 7.37% to $123.8 million in 2026.
• Business Quant data shows MYGN's Receivables at $123.8 million in Q1 2026, $115.3 million in Q4 2025, and $118.0 million in Q3 2025.